Candidaskin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine

A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of aCandidaskin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus the...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-12, Vol.31 (49), p.5806
Main Authors: Wang, Xuelian, Coleman, Hannah N, Nagarajan, Uma, Spencer, Horace J, Nakagawa, Mayumi
Format: Article
Language:English
Subjects:
Cell growth
Cervical cancer
Clinical trials
Cytokines
Human papillomavirus
Infections
Lymphocytes
Pattern recognition
Peptides
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of aCandidaskin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus therapeutic vaccine. The goal of this current study was to investigate the mechanisms of howCandidaenhances the vaccine immune responses. Maturation effects on Langerhans cells, capacity to proliferate T-cells, expression of cytokines and pattern recognition receptors by Langerhans cells, and ability to induce Th1, Th2, and Th17 responses were investigated in healthy subjects. The vaccine, human papillomavirus peptides withCandida, demonstrated partial maturation effects on Langerhans cells indicated by significantly up-regulated CD40 (p=0.00007) and CD80 (p
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2013.10.014